GO:0003835 beta-galactoside alpha-2,6-sialyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003835 describes the enzymatic activity that transfers sialic acid from CMP-N-acetylneuraminate to the 6-position of terminal galactose on glycoproteins and glycolipids.
• The reaction is catalyzed by ST6GAL1 in humans and is a key regulator of terminal glycosylation, influencing cell surface sialylation [1,6].
• ST6GAL1 expression is transcriptionally regulated by factors such as dexamethasone, interferon alpha-2b, and the transcription factor CTCF [3,4,5,7].
• Altered alpha-2,6-sialyltransferase activity is linked to cancer progression, including breast cancer where ST6GAL1 inhibits the Hippo pathway.
• The enzyme is also implicated in immune regulation, as ST6GAL1 upregulates sialylation of anti-citrullinated protein antibodies in rheumatoid arthritis.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect the causal roles of ST6GAL1 and related genes in disease [1,7].
Description
GO:0003835, beta-galactoside alpha-2,6-sialyltransferase activity, is a molecular function that catalyzes the transfer of sialic acid from CMP-N-acetylneuraminate to the 6-position of a terminal galactose residue on glycoproteins and glycolipids. This enzymatic activity is essential for the biosynthesis of sialylated glycans, which are critical for cell-cell communication, immune recognition, and signal transduction [1,6]. In humans, the primary enzyme responsible for this activity is ST6GAL1, a Golgi-resident type II membrane protein. The reaction produces N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl derivatives, which are abundant on the surface of many cell types and modulate interactions with lectins such as siglecs and selectins [1,7]. Researchers study this activity because it plays a central role in development, differentiation, and disease. For example, differentiation-dependent expression of ST6GAL1 mRNA has been observed in colon carcinoma CaCo-2 cells, suggesting a role in epithelial cell maturation. In breast cancer cells, ST6GAL1 inhibits the Hippo pathway, thereby promoting tumorigenesis. Moreover, ST6GAL1-mediated sialylation of anti-citrullinated protein antibodies contributes to the pathogenesis of rheumatoid arthritis. These findings underscore the importance of understanding the regulation and function of beta-galactoside alpha-2,6-sialyltransferase activity in both health and disease. The activity is tightly regulated at the transcriptional level by hormones, cytokines, and transcription factors. Dexamethasone induces ST6GAL1 gene expression in rat fibroblasts and hepatocytes [3,4], while interferon alpha-2b modulates its expression in rat testes. The transcription factor CTCF specifically upregulates ST6GAL1 in rheumatoid arthritis, linking epigenetic regulation to sialylation. Given its broad impact, GO:0003835 is a focal point for glycobiology research and therapeutic targeting.
beta-galactoside alpha-2,6-sialyltransferase activity At A Glance
| GO ID | GO:0003835 |
|---|---|
| GO term | beta-galactoside alpha-2,6-sialyltransferase activity |
| Ontology | molecular_function |
| Synonym | beta-galactosamide alpha-2,6-sialyltransferase activity; beta-galactoside alpha-(2,6)-sialyltransferase; CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase activity; lactosylceramide alpha-2,6-N-sialyltransferase |
| Major function | Transfer of sialic acid to terminal galactose residues on glycoproteins and glycolipids, forming alpha-2,6 linkages. |
| Reaction | CMP-N-acetylneuraminate + beta-D-galactoside = N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl derivative + CMP + H+. |
| Cellular location | Golgi apparatus membrane. |
| Representative enzyme | ST6GAL1 (beta-galactoside alpha-2,6-sialyltransferase 1). |
| Regulation | Transcriptional regulation by dexamethasone, interferon alpha-2b, and CTCF [3,4,5,7]. |
What Is GO:0003835?
According to the Gene Ontology, GO:0003835 (beta-galactoside alpha-2,6-sialyltransferase activity) is defined as the catalysis of the reaction: CMP-N-acetylneuraminate + beta-D-galactoside = N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl derivative + CMP + H+. In simpler terms, this activity attaches a sialic acid molecule to a galactose sugar on a protein or lipid, specifically forming an alpha-2,6 linkage. This modification is a type of glycosylation that occurs in the Golgi apparatus and is mediated by enzymes known as sialyltransferases, with ST6GAL1 being the prototypical human enzyme.
Why Is beta-galactoside alpha-2,6-sialyltransferase activity Important in Cell Biology?
Beta-galactoside alpha-2,6-sialyltransferase activity is crucial because it controls the addition of sialic acid to glycans, a modification that affects protein stability, cell adhesion, and immune recognition [1,6]. Dysregulation of this activity is associated with cancer, autoimmune diseases, and infections, making it a potential biomarker and therapeutic target [1,7].
• Regulates cell surface sialylation, impacting cell-cell and cell-matrix interactions.
• Modulates immune responses by altering antibody sialylation, as seen in rheumatoid arthritis.
• Influences cancer progression, including breast cancer through Hippo pathway inhibition.
• Plays a role in differentiation, as shown in colon carcinoma CaCo-2 cells.
• Is induced by dexamethasone, linking glucocorticoid signaling to glycosylation [3,4].
• Is modulated by interferon alpha-2b in reproductive tissues.
• Contributes to viral pathogenesis, as suggested by RNA profiling of TBEV-infected neural cells.
• Serves as a target for glycoengineering and therapeutic antibody development [1,7].
• Provides a model for studying transcriptional regulation of glycosyltransferases.
What Happens During beta-galactoside alpha-2,6-sialyltransferase activity?
Substrate Recognition and Binding
In simple terms: The enzyme grabs the sugar donor and the target sugar.
The enzyme binds CMP-N-acetylneuraminate (the sialic acid donor) and a beta-D-galactoside acceptor, which is typically part of a glycoprotein or glycolipid. This binding is facilitated by conserved sialylmotif sequences in the catalytic domain of ST6GAL1.
Catalytic Transfer and Linkage Formation
In simple terms: The enzyme attaches sialic acid to galactose with a specific 2,6 linkage.
The catalytic reaction proceeds via a ping-pong mechanism where sialic acid is transferred from CMP-N-acetylneuraminate to the 6-hydroxyl group of terminal galactose, forming an alpha-2,6 linkage and releasing CMP and H+. This modification is irreversible and occurs in the trans-Golgi network.
Product Release and Glycan Maturation
In simple terms: The modified sugar is released and becomes part of the mature glycan.
After transfer, the sialylated product is released and further processed by other glycosyltransferases, contributing to the mature glycan structures on cell surface proteins and lipids [1,6]. These sialylated glycans are then displayed on the cell surface, where they mediate interactions with lectins.
Transcriptional Regulation of Enzyme Levels
In simple terms: The amount of enzyme is controlled by hormones and transcription factors.
The expression of ST6GAL1 is regulated at the transcriptional level. Dexamethasone induces ST6GAL1 mRNA in rat fibroblasts and hepatocytes [3,4], while interferon alpha-2b modulates its expression in rat testes. The transcription factor CTCF specifically upregulates ST6GAL1 in rheumatoid arthritis. Additionally, differentiation-dependent expression is observed in colon carcinoma cells.
Key Genes Involved in GO:0003835 beta-galactoside alpha-2,6-sialyltransferase activity
The following genes and proteins are directly involved in or regulate beta-galactoside alpha-2,6-sialyltransferase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ST6GAL1 | Catalyzes the transfer of sialic acid to galactose in alpha-2,6 linkage | Key enzyme for GO:0003835; implicated in cancer and immune diseases [1,7] |
| CTCF | Transcription factor that upregulates ST6GAL1 | Regulates ST6GAL1 expression in rheumatoid arthritis |
| CMP-N-acetylneuraminate | Sialic acid donor substrate | Essential co-substrate for the reaction |
| beta-D-galactoside | Acceptor substrate on glycoproteins and glycolipids | Determines target specificity |
| ST6GAL2 | Another alpha-2,6-sialyltransferase with similar activity | Potential redundancy or tissue-specific functions |
| B4GALT1 | Beta-1,4-galactosyltransferase that creates acceptor sites | Provides terminal galactose for sialylation |
| SLC35A1 | CMP-sialic acid transporter | Supplies CMP-sialic acid to the Golgi |
| GNE | UDP-GlcNAc 2-epimerase/ManNAc kinase | Involved in sialic acid biosynthesis |
| NANS | Sialic acid synthase | Produces sialic acid precursors |
| CMAS | CMP-sialic acid synthetase | Activates sialic acid to CMP-sialic acid |
| SIGLEC1 | Sialic acid-binding lectin | Mediates interactions with sialylated glycans |
| SELPLG | Selectin P ligand | Sialylation affects leukocyte adhesion |
| MUC1 | Mucin 1 | Sialylation alters its function in cancer |
| EGFR | Epidermal growth factor receptor | Sialylation modulates signaling |
| ITGB1 | Integrin beta 1 | Sialylation affects cell adhesion |
| CD44 | Cell surface glycoprotein | Sialylation influences cancer stemness |
| PTPRC | CD45 antigen | Sialylation regulates immune cell signaling |
| Hippo pathway components | YAP/TAZ | ST6GAL1 inhibits Hippo pathway in breast cancer |
How Is beta-galactoside alpha-2,6-sialyltransferase activity Regulated?
Beta-galactoside alpha-2,6-sialyltransferase activity is primarily regulated at the transcriptional level. Dexamethasone induces ST6GAL1 gene expression in rat fibroblasts and hepatocytes [3,4]. Interferon alpha-2b modulates ST6GAL1 expression in rat testes. The transcription factor CTCF specifically upregulates ST6GAL1 in rheumatoid arthritis, linking epigenetic regulation to sialylation. Additionally, differentiation-dependent expression of ST6GAL1 mRNA has been observed in colon carcinoma CaCo-2 cells. The gene organization and transcriptional regulation of terminal glycosylation have been studied in detail.
beta-galactoside alpha-2,6-sialyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ST6GAL1 | Breast cancer, Hippo pathway inhibition | Knockout and overexpression in breast cancer cell lines |
| ST6GAL1 | Rheumatoid arthritis, antibody sialylation | Knockout in B cells or knock-in of CTCF binding site |
| ST6GAL1 | Colon carcinoma differentiation | Differentiation-induced expression in CaCo-2 cells |
| ST6GAL1 | Viral infection (TBEV) | Infected neuron/astrocyte models |
| ST6GAL1 | Testicular function | Interferon alpha-2b treated rat testes |
Cancer
ST6GAL1-mediated alpha-2,6-sialylation is frequently upregulated in cancers and promotes tumor progression. In breast cancer cells, ST6GAL1 inhibits the Hippo pathway, leading to increased cell proliferation and migration. The enzyme also enhances sialylation of cell surface receptors, contributing to metastasis.
Rheumatoid Arthritis
In rheumatoid arthritis, the transcription factor CTCF upregulates ST6GAL1, which in turn increases sialylation of anti-citrullinated protein antibodies, potentially exacerbating autoimmune responses.
Infectious Diseases
Integrative RNA profiling of TBEV-infected neurons and astrocytes revealed changes in sialyltransferase expression, suggesting a role for alpha-2,6-sialylation in viral pathogenesis.
From beta-galactoside alpha-2,6-sialyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ST6GAL1 loss affect tumor growth? | ST6GAL1 knockout in breast cancer cell lines |
| How does CTCF regulate ST6GAL1 in rheumatoid arthritis? | CTCF knockout or knockdown in B cells |
| What is the role of ST6GAL1 in differentiation? | ST6GAL1 knockout in CaCo-2 cells |
| Does dexamethasone induction require specific response elements? | Point mutations in ST6GAL1 promoter [3,4] |
| Can sialylation be redirected to other linkages? | Knock-in of ST6GAL1 catalytic domain mutants |
| What is the effect of ST6GAL1 overexpression on cell signaling? | Overexpression of ST6GAL1 in cancer cells |
How to Study the beta-galactoside alpha-2,6-sialyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Glycan composition and sialylation linkages | Profiling alpha-2,6-sialylation in cells |
| Lectin blotting | Presence of alpha-2,6-sialic acid | Detecting sialylation changes |
| Flow cytometry | Cell surface sialylation | Immune cell phenotyping |
| qRT-PCR | ST6GAL1 mRNA levels | Transcriptional regulation studies [3,4,5] |
| Western blotting | ST6GAL1 protein levels | Validating knockout or overexpression |
| Luciferase reporter | Promoter activity | Mapping regulatory elements [3,4,7] |
| CRISPR screening | Gene essentiality or synthetic lethality | Identifying modifiers of sialylation |
Glycan Analysis by Mass Spectrometry
Mass spectrometry-based glycomics can profile sialylated glycans to quantify alpha-2,6-sialylation on glycoproteins and glycolipids.
Lectin Blotting and Flow Cytometry
Sambucus nigra agglutinin (SNA) specifically binds alpha-2,6-sialic acid and can be used in lectin blots or flow cytometry to detect cell surface sialylation.
Transcriptional Reporter Assays
Luciferase reporter assays using ST6GAL1 promoter constructs can dissect transcriptional regulation by dexamethasone, interferon, or CTCF [3,4,7].
CRISPR-Cas9 Genome Editing
Knockout, knock-in, and point mutation models allow functional dissection of ST6GAL1 and its regulators in disease contexts [1,7].
How CRISPR Can Be Used to Study GO:0003835 beta-galactoside alpha-2,6-sialyltransferase activity
Knockout
CRISPR knockout of ST6GAL1 eliminates alpha-2,6-sialyltransferase activity, enabling studies of its role in cancer, immune regulation, and differentiation [1,7].
Point Mutation
Point mutations in the catalytic domain of ST6GAL1 can abolish enzymatic activity while preserving protein structure, useful for dissecting catalytic versus non-catalytic functions.
Knock-in
Knock-in of tagged ST6GAL1 (e.g., HA or GFP) allows localization and interaction studies, while knock-in of disease-associated variants can model human phenotypes.
Overexpression
Overexpression of ST6GAL1 in cell lines increases alpha-2,6-sialylation and can drive phenotypes such as Hippo pathway inhibition in breast cancer.
How EDITGENE Supports beta-galactoside alpha-2,6-sialyltransferase activity Research
Researchers studying beta-galactoside alpha-2,6-sialyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes like ST6GAL1 and its regulators.
Contact EDITGENE today to design your custom CRISPR model for beta-galactoside alpha-2,6-sialyltransferase activity research.
Frequently Asked Questions About beta-galactoside alpha-2,6-sialyltransferase activity
What is beta-galactoside alpha-2,6-sialyltransferase activity?
It is the enzymatic activity that transfers sialic acid to the 6-position of galactose on glycoproteins and glycolipids, defined by GO:0003835.
What genes are involved in beta-galactoside alpha-2,6-sialyltransferase activity?
The primary gene is ST6GAL1, but other genes like CTCF regulate its expression [1,7].
What is the role of ST6GAL1 in cancer?
ST6GAL1 promotes cancer progression by inhibiting the Hippo pathway and enhancing sialylation of cell surface receptors.
How is beta-galactoside alpha-2,6-sialyltransferase activity regulated?
It is regulated transcriptionally by dexamethasone, interferon alpha-2b, and CTCF [3,4,5,7].
What diseases are associated with alpha-2,6-sialyltransferase activity?
It is linked to breast cancer, rheumatoid arthritis, and viral infections [1,2,7].
What methods are used to study alpha-2,6-sialylation?
Mass spectrometry, lectin blotting, flow cytometry, and CRISPR screens are commonly used.
Can CRISPR knockout of ST6GAL1 affect cell behavior?
Yes, knockout reduces sialylation and can reverse cancer phenotypes.
What is the reaction catalyzed by GO:0003835?
CMP-N-acetylneuraminate + beta-D-galactoside = N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl derivative + CMP + H+.
Is ST6GAL1 the only enzyme with this activity?
ST6GAL2 also exhibits similar activity, but ST6GAL1 is the major human enzyme.
How can I model ST6GAL1 mutations in the lab?
EDITGENE provides CRISPR knockout, point mutation, knock-in, and overexpression services to model ST6GAL1 variants.
Conclusion
Beta-galactoside alpha-2,6-sialyltransferase activity (GO:0003835) is a fundamental enzymatic function that shapes the sialylation landscape of cells. Its dysregulation contributes to cancer, autoimmune diseases, and infections, making it a critical research focus. Understanding its regulation and function through CRISPR-based models will pave the way for novel therapeutic strategies.
References
- 1. Hang Q et al.. 2025. Inhibitory effects of β-galactoside α2,6-sialyltransferase 1 on the Hippo pathway in breast cancer cells.. J Biol Chem 301(10):110266 PMID: 40409546
- 2. Selinger M et al.. 2022. Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors.. Comput Struct Biotechnol J 20:2759-2777 PMID: 35685361
- 3. Wang XC et al.. 1989. Regulation of beta-galactoside alpha 2,6-sialyltransferase gene expression by dexamethasone.. J Biol Chem 264(3):1854-9 PMID: 2912988
- 4. Vandamme V et al.. 1993. Transcriptional induction of beta-galactoside alpha-2,6-sialyltransferase in rat fibroblast by dexamethasone.. Eur J Biochem 211(1-2):135-40 PMID: 7678804
- 5. Bessler H et al.. 1995. Interferon alpha-2b modulates beta-galactoside alpha-2,6-sialyltransferase gene expression in rat testes.. Biol Reprod 53(6):1474-7 PMID: 8562705
- 6. Dall'Olio F et al.. 1996. Differentiation -dependent expression of human beta-galactoside alpha 2,6-sialyltransferase mRNA in colon carcinoma CaCo-2 cells.. Glycoconj J 13(1):115-21 PMID: 8785482
- 7. Zhao H et al.. 2024. CCCTC-binding factor: the specific transcription factor of β-galactoside α-2,6-sialyltransferase 1 that upregulates the sialylation of anti-citrullinated protein antibodies in rheumatoid arthritis.. Rheumatology (Oxford) 63(3):826-836 PMID: 37326830
- 8. Svensson EC et al.. 1990. Organization of the beta-galactoside alpha 2,6-sialyltransferase gene. Evidence for the transcriptional regulation of terminal glycosylation.. J Biol Chem 265(34):20863-8 PMID: 2249992
